FE 999049 is a gonadotropin preparation containing recombinant human follicle stimulating
hormone (rhFSH) under development by Ferring Pharmaceuticals. It is intended for controlled
ovarian stimulation for the development of multiple follicles in women undergoing assisted
reproductive technologies (ART) such as in vitro fertilisation (IVF) or intracytoplasmic
sperm injection (ICSI) cycle. In previous trials the exposure to and dose proportionality of
FE 999049 in a clinically relevant dose range in Caucasian and Japanese healthy women have
been shown to be very similar. This is a trial in healthy Chinese women investigating the
pharmacokinetics, safety, and tolerability of a single subcutaneous dose of FE 999049.